Please login to the form below

Not currently logged in
Email:
Password:

David Noble to leave Edelman

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.

Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.

Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.

Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."

The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.

13th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics